ION-IP
ION-IP provides advanced, intelligent solutions in communications infrastructure in order to optimize availability, reliability, security and performance of applications and data streams over the internet.
ION-IP
Industry:
Communications Infrastructure Intelligent Systems
Founded:
2003-01-01
Address:
Veenendaal, Utrecht, The Netherlands
Country:
The Netherlands
Website Url:
http://www.ionip.com
Total Employee:
51+
Status:
Active
Contact:
+310318584848
Email Addresses:
[email protected]
Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail IPv6 Microsoft Azure DNS Google Maps API CloudFront Microsoft Microsoft Azure Twitter Tweet Button
Current Advisors List
Official Site Inspections
http://www.ionip.com
- Host name: telindus-10.colo.bit.nl
- IP address: 87.251.53.187
- Location: Almere Stad Netherlands
- Latitude: 52.4054
- Longitude: 5.3218
- Timezone: Europe/Amsterdam
- Postal: 1336
More informations about "Ion-ip"
Who We Are - ionis.com
Dec 19, 2024 Ionis’ science is driven by a deep understanding of the genetic foundations of diseases and a commitment to advancing next-generation technology, coupled with an …See details»
Ionis enters new chapter in 2025 as commercial-stage biotech with ...
Jan 13, 2025 "With last month's U.S. approval and launch of TRYNGOLZA™ (olezarsen) as the first-ever therapy for familial chylomicronemia syndrome and the potential approval of …See details»
Corporate Presentation - Ionis Pharmaceuticals, Inc.
Describing Ionis’goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should ... Innovative and scalable commercial organization in …See details»
Our Responsibility to Create a Healthier Future | IONIS
At Ionis, we work with a sense of urgency to discover, develop and deliver medicines to create a better future for people with serious diseases. We believe operating responsibly and …See details»
Grants & Sponsorships: Medical & Research | IONIS
Contact Information. If you have any questions regarding the Ionis IME Grant program, please email [email protected].. For Technical Support with the Ionis Grant Portal, please …See details»
Ionis announces GSK has advanced bepirovirsen into Phase 3 …
Feb 1, 2023 "The initiation of this Phase 3 program is an important step closer to delivering novel medicines to HBV patients in need," said Richard S. Geary, Ph.D., Ionis' executive vice …See details»
SEC Filings - Ionis Pharmaceuticals, Inc.
Mar 4, 2025 The Investor Relations website contains information about Ionis Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts.See details»
Ionis launches paired HCP and patient campaigns for Tryngolza
5 days ago Ionis built its current paired campaigns on listening to people with FCS. “When we were building the campaign, we did a number of things, and we did this on the physician and …See details»
Ionis and Ono announce global license agreement for sapablursen …
Mar 11, 2025 CARLSBAD, Calif. & OSAKA, Japan, March 11, 2025--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Ono Pharmaceutical Co., Ltd (Ono), today announced that the two …See details»
Ionis Pharmaceuticals Mission, Benefits, and Work Culture - Indeed
Ionis Pharmaceuticals, Inc., is headquartered in Carlsbad, California, with offices in Boston, Massachusetts, and Dublin, Ireland. For more than 30 years, Ionis has been the leader in RNA …See details»
Demographics & Equal Opportunity Employer (EEO) | IONIS
At every level of our organization, we aim to reflect the diversity of the communities and patients we serve. We track, measure and publicly report on our progress. In addition to the gender …See details»
Ionis enters agreement with Roche for two novel RNA-targeted …
Sep 27, 2023 These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended Dec. 31, 2022, and the most recent …See details»
Ionis announces plan for new manufacturing facility in Oceanside, …
Oct 12, 2022 These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended Dec. 31, 2021, and the most recent …See details»
Ionis to present at 43rd Annual J.P. Morgan Healthcare Conference
Jan 8, 2025 Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Brett P. Monia, Ph.D., chief executive officer, will present a company overview at the 43rd Annual J.P. Morgan …See details»
Ono Enters into License Agreement with Ionis Pharmaceuticals for ...
Mar 12, 2025 Ionis will remain responsible for the completion of the ongoing Phase 2 IMPRSSION study, while ONO will be solely responsible for subsequent development, …See details»
Our Medicines | IONIS
Ionis has discovered and developed six currently marketed medicines for serious diseases, including breakthrough medicines for neurologic and cardiovascular diseases. For more …See details»
Ono earmarks $940m to gain rare blood cancer therapy from Ionis
Mar 12, 2025 Ono and Ionis state that by increasing the production of this hormone, sapablursen has the potential to positively impact blood diseases such as PV. If approved, sapablursen …See details»
Ionis announces expanded licensing agreement with Otsuka in …
Jun 18, 2024 Ionis plans to file a New Drug Application with the U.S. Food and Drug Administration (FDA) this year, and will independently launch donidalorsen in the U.S., if …See details»
Ionis (Ionis) - 药物管线_专利_临床试验_投融营收_最新药 …
了解Ionis (Ionis)公司的药物管线，治疗领域，技术平台，以及它的726篇新闻，疾病领域:内分泌与代谢疾病，肿瘤，技术平台:ASO，药物:ISIS-329993，AZD-5312，IONIS …See details»
Pipeline of RNA-Targeted Therapies - Ionis Pharmaceuticals, Inc.
Mar 11, 2025 Olezarsen, formerly known as IONIS-APOCIII-L Rx and AKCEA-APOCIII-L Rx, is an investigational RNA-targeted medicine being evaluated for people at risk of disease due to …See details»